Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 64(1), 9–29 (2014).
  MedlineGoogle Scholar
• 2 McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334(1), 1–6 (1996).
  Medline CASGoogle Scholar
• 3 Bookman MA. The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer. Ann. Oncol. 21(Suppl. 7), vii211–vii217 (2010).
  MedlineGoogle Scholar
• 4 Dizon DS, Weitzen S, Rojan A et al. Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer. Gynecol. Oncol. 100(2), 417–421 (2006).
  Medline CASGoogle Scholar
• 5 Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB. Are three additional cycles of chemotherapy useful in patients with advanced-stage epithelial ovarian cancer after a complete response to six cycles of intravenous adjuvant paclitaxel and carboplatin? Jpn. J. Clin. Oncol. 38(6), 445–450 (2008).
  MedlineGoogle Scholar
• 6 Hanker LC, Loibl S, Burchardi N et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann. Oncol. 23(10), 2605–2612 (2012).
  Medline CASGoogle Scholar
• 7 Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108(2), 171–182 (2002).
  Medline CASGoogle Scholar
• 8 Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035), 913–917 (2005).
  Medline CASGoogle Scholar
• 9 Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035), 917–921 (2005).
  Medline CASGoogle Scholar
• 10 Menear KA, Adcock C, Boulter R et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J. Med. Chem. 51(20), 6581–6591 (2008).
  Medline CASGoogle Scholar
• 11 Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 23(16), 2825–2837 (2004).•• This is the RPh2 study (Study 19) that compared maintenance olaparib versus placebo following complete or partial response to chemotherapy in platinum-sensitive disease. The addition of olaparib markedly improved progression-free survival among all patients but especially among those with a germline BRCA mutation (hazard ratio: 18).
  Medline CASGoogle Scholar
• 12 Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366(15), 1382–1392 (2012).
  Medline CASGoogle Scholar
• 13 Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol. Oncol. 5(4), 387–393 (2011).
  Medline CASGoogle Scholar
• 14 Gelmon KA, Tischkowitz M, Mackay H et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a Phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12(9), 852–861 (2011).• This was one of the earlier Phase II trials to demonstrate significant activity as a single agent for olaparib in relapsed ovarian cancer patients who carry a germline BRCA mutation.
  Medline CASGoogle Scholar
• 15 Hay T, Matthews JR, Pietzka L et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res. 69(9), 3850–3855 (2009).
  Medline CASGoogle Scholar
• 16 Rottenberg S, Jaspers JE, Kersbergen A et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci. USA 105(44), 17079–17084 (2008).
  Medline CASGoogle Scholar
• 17 Evers B, Drost R, Schut E et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin. Cancer Res. 14(12), 3916–3925 (2008).
  Medline CASGoogle Scholar
• 18 Sessa C. Update on PARP1 inhibitors in ovarian cancer. Ann. Oncol. 22(Suppl. 8), viii72–viii76 (2011).
  MedlineGoogle Scholar
• 19 Mendes-Pereira AM, Martin SA, Brough R et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1(6–7), 315–322 (2009).
  Medline CASGoogle Scholar
• 20 Chen Y, Zhang L, Hao Q. Olaparib: a promising PARP inhibitor in ovarian cancer therapy. Arch. Gynecol. Obstet. 288(2), 367–374 (2013).
  Medline CASGoogle Scholar
• 21 Fong PC, Yap TA, Boss DS et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28(15), 2512–2519 (2010).
  Medline CASGoogle Scholar
• 22 Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361(2), 123–134 (2009).
  Medline CASGoogle Scholar
• 23 Liu JF, Tolaney SM, Birrer M et al. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur. J. Cancer 49(14), 2972–2978 (2013).
  Medline CASGoogle Scholar
• 24 Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376(9737), 245–251 (2010).
  Medline CASGoogle Scholar
• 25 Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised Phase 2 trial. Lancet Oncol. 15(8), 852–861 (2014).• This post hoc analysis is from Study 19.
  Medline CASGoogle Scholar
• 26 Oza A, Cibula D, Benzaquen AO et al. Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum sensitive recurrent serous ovarian cancer (PSR SOC): BRCA 1/2 mutation (BRCAm) and interim overall survival analyses. Eur. J. Cancer 49(Suppl. 2) (2013).
  MedlineGoogle Scholar
• 27 Liu JF, Barry WT, Birrer M et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised Phase 2 study. Lancet Oncol. 15(11), 1207–1214 (2014).•• This randomized Phase II trial in platinum-sensitive patients with and without BRCA mutations demonstrated the activity of single-agent olaparib but more importantly, demonstrated the synergistic effect of combination cediranib and olaparib among patients who were BRCA unknown or wild-type.
  Medline CASGoogle Scholar
• 28 Kaufman B, Shapira-Frommer R, Schmutzler RK et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 33(3), 244–250 (2015).•• This is the largest, Phase II, single-agent study performed in multiple tumors with germline BRCA mutations. It included a large number of platinum-resistant ovarian cancer patients and demonstrated a remarkably high response rate.
  Medline CASGoogle Scholar
• 29 Kaye SB, Lubinski J, Matulonis U et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J. Clin. Oncol. 30(4), 372–379 (2012).• This was an important trial randomizing patients with a germline BRCA mutation to one of two doses of olaparib versus pegylated liposomal doxorubicin. It not only demonstrated the similar activity of olaparib to a cytotoxic in this population but also demonstrated the chemosensitivity of BRCA patients in that pegylated liposomal doxorubicin outperformed as compared with historical data in non-BRCA patients.
  Medline CASGoogle Scholar
• 30 Safra T, Rogowski O, Muggia FM. The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer. Int. J. Gynecol. Cancer 24(3), 488–495 (2014).
  MedlineGoogle Scholar
• 31 Oza AM, Cibula D, Benzaquen AO et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised Phase 2 trial. Lancet Oncol. 16(1), 87–97 (2015).
  Medline CASGoogle Scholar
• 32 Oza A, Cibula D, Benzaquen A, Poole C, Mathijssen R, Sonke G. Olaparib plus chemotherapy followed by maintenance monotherapy inpatients with platinum sensitive recurrent serous ovarian cancer (abstract). J. Clin. Oncol. 30, Abstract 28 (2012).
  MedlineGoogle Scholar
• 33 Matulonis UA, Berlin S, Ivy P et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J. Clin. Oncol. 27(33), 5601–5606 (2009).
  Medline CASGoogle Scholar
• 34 Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, Glazer PM. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc. Natl Acad. Sci. USA 107(5), 2201–2206 (2010).
  Medline CASGoogle Scholar
• 35 Tentori L, Lacal PM, Muzi A et al. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur. J. Cancer 43(14), 2124–2133 (2007).
  Medline CASGoogle Scholar
• 36 Molife L, Mateo J, McGoldrick T et al. Safety and efficacy results from two randomized expansions of a Phase I study of a tablet formulation or the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations. J. Clin. Oncol. 30(Suppl.), Abstract 3048 (2012).
  MedlineGoogle Scholar
• 37 Mateo J, Friedlander M, Sessa C. Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formation. Eur. J. Cancer 49(Suppl. 2), Abstract 801 (2013).
  Google Scholar
• 38 Zhang S, Royer R, Li S et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol. Oncol. 121(2), 353–357 (2011).
  Medline CASGoogle Scholar
• 39 Lheureux S, Ledermann J, Kaye S et al. Characterization of ovarian cancer long-term responders on olaparib (abstract). J. Clin. Oncol. 32(5s), Abstract 5534 (2014).
  Google Scholar
• 40 Dougherty B, Ledermann J, Lai Z et al. Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients with platinum-sensitive, relapsed serous ovarian cancer (abstract). J. Clin. Oncol. 32(5s), Abstract 5536 (2014).
  MedlineGoogle Scholar
• 41 Ang JE, Gourley C, Powell CB et al. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin. Cancer Res. 19(19), 5485–5493 (2013).
  Medline CASGoogle Scholar
• 42 Fenaux P, Morel P, Lai JL. Cytogenetics of myelodysplastic syndromes. Semin. Hematol. 33(2), 127–138 (1996).
  Medline CASGoogle Scholar